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Introduction: Variations in human T cell lymphotropic virus type 1 (HTLV-1) proviral load
(PVL) in infected individuals over time are not well understood.
Objective: To evaluate the evolution of proviral load in asymptomatic individuals and
HAM/TSP patients in order to help determine periodicity for measuring proviral load.
Methods: A group of 104 HTLV-1 infected patients, followed at the HTLV reference center
in Salvador, Brazil, were included in the study (70 asymptomatic and 34 HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) patients). HTLV-1 PVL was measured
using real-time polymerase chain reaction (PCR) at baseline and again at another point,
either ≤ 12 months, between 12-24 months, or ≥ 24 months.
Results: HAM/TSP patients had higher PVL (ranging from 11,041 to 317,009 copies/106 PBMC)
when compared to asymptomatic individuals (ranging from0 to 68,228 copies/106 PBMC). No
statistically signiﬁcant differenceswere observed in themediansof PVL inHAM/TSPpatients
or asymptomatic individuals over time. However, in asymptomatic individuals with a PVL
below 50,000 copies/106 PBMC, a statistically signiﬁcant two-fold increase was observed over
time.
Conclusion: HTLV-1-PVL remained stable in both asymptomatic individuals and HAM/TSPpatients over time. Frequent monitoring of asymptomatic individuals with low PVLs is rec-
ommended and further studies should be conducted to assess the course of PVL in these
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Japan, Central and West Africa, the Caribbean Islands, and
Central and South America.1 Brazil appears to have the high-
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world, and it is estimated that 1.7% of the general pop-
ulation of the city of Salvador, in the state of Bahia, is
infected by the virus.2 HTLV-1 is the etiological agent of
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HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), adult T-cell leukemia (ATL), uveitis,3–5 and kera-
toconjuntivitis sicca (KCS).6 The infection is also associated
with an increasing occurrence of infectious diseases, such
as infective dermatitis in children,7 tuberculosis,8,9 dissem-
inated strongyloidiasis,10,11 and scabies.12 The majority of
infected individuals remain asymptomatic over their lifetime,
and less than 5% will develop an HTVL-1-associated dis-
ease. The HTLV-1-PVL may represent a biological marker of
disease development, especially HAM/TSP. A higher HTLV-1
proviral load (PVL) is observed in HAM/TSP patients com-
pared to asymptomatic carriers.13–15 However, the progression
of the HTLV-1-PVL in infected individuals remains unclear.
This study evaluated the course of HLTV-1-PVL among asymp-
tomatic and HAM/TSP patients at baseline at intervals of less
than 12 months, 12 to 24 months, and more than 24 months.
The authors were interested in evaluating the evolution
of proviral load in asymptomatic individuals and HAM/TSP
patients in order to help determining an ideal periodicity for
measuring proviral load. The results suggest that the HTLV-1-
PVLs of patients have a stable course in the evaluated periods
of time.
Methods
This is a retrospective study with a non-probability sam-
pling. The patients selected for the study were followed at
the Escola Bahiana de Medicina e Saúde Pública, Centro de
Referência de HTLV, in Salvador, Northeast Brazil, from 2005
to 2009. This center is a free outpatient clinic that since 2002
has provided comprehensive care for more than 1,400 HTLV-
1 infected individuals. Approximately 500 patients regularly
attend the clinic twice a year. All patients with at least two
HTLV-1-PVL measurements in intervals of up to 12 months,
12 to 24 months, and more than 24 months, and one neu-
rological evaluation were included in the study. Data were
obtained from medical charts. The revised criteria proposed
by the World Health Organization in 1989 were used in order
to diagnosis HAM/TSP. All asymptomatic individuals were
evaluated by a neurologist and did not present any neuro-
logical signs. Patients co-infected with HIV and/or HCV were
excluded from the study. This study was approved by the
Institutional Review Board of the Fundac¸ão Oswaldo Cruz.
Peripheral blood mononuclear cells (PBMCs) were obtained
from ethylenediaminetetraacetic acid (EDTA) blood by density
gradient centrifugation, and cryopreserved until use. DNAwas
extracted using a spin column DNA extraction system (QUIA-
GEN, Germany). HTLV-1-PVL was measured using a real-time
TaqMan PCR method, in accordance with Dehéee et al. Albu-
min DNA was used as an endogenous reference. The value of
HTLV-1-PVL was reported as the [(HTLV-1 average copy num-
ber)/(albumin average copy number)] x 2 x 106 and expressed
as the number of HTLV-1 copies per 106 PBMCs. All HTLV-1-PVL
measurements were performed in duplicates. The analysis
was repeated when there was a variation greater than 30%
between duplicate values of HTLV-I or albumin DNA copy
numbers. Median values of HTLV-1-PVL were calculated for
the different groups of patients. Wilcoxon matched pairs test
was used for comparison of medians. The level of statistical12;16(4):357–360
signiﬁcance of the type-1 errorwas set at less than 0.05. Graph-
pad (5.0) was used for statistical analyses.
Results
Out of a total of 104 HTLV-infected patients, 69 were females
(66.3%). The median age of the individuals was 49.5 years old
(IQR: 40-57). Seventy patients were asymptomatic and 34 had
HAM/TSP. The median of HTLV-1-PVL of HAM/TSP patients
was higher (ranging between 11,041 and 317,009 copies/106
PBMC) when compared to asymptomatic individuals (ranging
between undetectable and 68,228 copies/106 PBMC) at all time
points evaluated. There was no signiﬁcant difference between
the medians of HTLV-1-PVL of asymptomatic carriers and
HAM/TSP patients at baseline and in a second measurement
after an intervals of up to 12 months [median 7 (IQR: 2-11)],
12 to 24 months [median 18 (IQR: 13-24)], and more than 24
months [median29 (IQR: 25-43)] (Table 1).Whenasymptomatic
individuals were stratiﬁed according to HTLV-1- PVL (above
or below 50,000 copies/106 PBMC), a statistically signiﬁcant
two-fold increase in HTLV-1-PVL was observed in individuals
with low HTLV-1-PVLs over time, speciﬁcally when the second
measurement was taken ≥ 12 months after baseline (Table 2).
Discussion
The present study demonstrated that the HTLV-1-PVLs of
both asymptomatic and HAM/TSP patients remain stable
for a period of more than two years. Moreover, the medi-
ans of HTLV-1-PVL were higher in the HAM/TSP patients
than in asymptomatic carriers, as demonstrated in previ-
ous studies.13–16 Several studies indicated that HTLV-1-PVLs
remain stable for long periods of time in both asymptomatic
and HAM/TSP patients. Taylor et al. showed that proviral load
remain stable over many months (maximum 64 months).17
However, these studies were heterogeneous regarding their
methodology, sample size, and the period of time assessed.
HTLV-1-PVL could remain relatively constant over a follow-
up period from 24 months to 10.4 years.17–19 Another study
demonstrated that the HTLV-1-PVL of HAM/TSP patients may
present a four- to ten-fold ﬂuctuation in a one-three-year
follow-up period, with variations in the clinical course of
HAM/TSP disease.20 Recently, a HTLV-1-PVL above 50,000
copies/106 PBMC was identiﬁed as the best cutoff value to dis-
tinguish asymptomatic individuals from HAM/TSP patients.15
In the present study, a two-fold increase was observed in
asymptomatic individuals with proviral loads below 50,000
copies/106 PBMC (which corresponded to 5% of HTLV-1-
infected PBMC) over a period of 12 months to >24 months, yet
proviral loads remained below the cutoff level. No difference
was observed in HTLV-1-PVLs from HAM/TSP patients over
time. Recently, Furtado et al.,21 using a cutoff value of 1%HTLV-
infected PBMC found that the HTLV-1-PVL was more stable
in asymptomatic carriers than in HAM/TSP patients, but this
difference was not signiﬁcant. The different methodologies
used to measure viral load in both studies could explain the
discrepancy between the established cutoff values. While Fur-
tado et al.21 used whole blood as the source of DNA samples,
in this study DNA was extracted from 1x106 PBMC. Similarly
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Table 1 – Proviral load variations at baseline and in intervals of 12 months, 12 to 24 months, and more than 24 months in
asymptomatic carriers and HAM/TSP patients.
Interval (months) n Age (years) Median time
(months)
Gender (%
female)
HTLV-1 proviral
loada (baseline)
HTLV-1 proviral
loadb (2nd point)
p- valuec
Asymptomatic
<12 27 45 (34-49) 5 (0.4-12) 66 9,157 (1,015-37,410) 6,780 (150-42,368) 0.6
≥ 12 to <24 31 51 (37-59.5) 18 (13-23) 77 5,075 (436-35,389) 3,422 (0-68,228) 0.8
≥ 24 12 41 (23-49) 29 (25-43) 75 12,334 (1,590-43,712) 15,205 (148-52,091) 0.6
HAM/TSP
<12 11 52 (39.5-59.5) 7 (2-11) 71 86,560 (31,762-186,633) 88,889 (41,557-149,008) 0.9
≥ 12 and <24 13 54 (45.5-62) 18 (13-24) 69 118,842 (15,392-317,009) 85,916 (11,041-205,807) 0.4
≥ 24 10 49.5 (40-64) 30 (25-34) 50 73,911 (19,384-90,380) 73,885 (37,690-109,860) 0.7
a Variables expressed as median (25th percentile, 75th percentile).
b Copies/106 PBMC.
c Wilcoxon test was used to compare the medians of proviral load.
Table 2 – Proviral load variations at baseline and in intervals of 12 months, 12 to 24 months, and more than 24 months in
asymptomatic individuals with low proviral load (<50,000copies/106PBMC).
Interval (months) n Median time
(months)
HTLV-1 proviral
loada (baseline)
HTLV-1 proviral
loadb (2nd point)
p-valuec
< 12 21 5 (3-9) 3,305 (97-26,481) 3,451 (282-12,040) 0,6
≥ 12 and <24 29 18 (14-19) 2,676 (8-27,145) 4,549 (133-53,541) 0,01
≥ 24 11 30 (26-32) 6,114 (265-28,665) 11,530 (109-57,142) 0,02
a Variables expressed as median (25th percentile, 75th percentile).
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o Furtado et al., no correlation could be found between HTLV-
-PVL and severity of HAM/TSP disease, age at disease onset,
r duration of illness (data not shown).
The HTLV-1 -PVL has been described as a marker of disease
evelopment, especially HAM/TSP.13–16 An increased HTLV-1-
VL is also present in patients with other HTLV-1-associated
iseases, such as infective dermatitis,22 ATL,23 KCS,6 as well
s in HTLV-1-infected patients with rheumatoid arthritis or
ther connective tissue diseases.24 PVL represents the amount
f virus integrated into the genome. It is maintained mainly
hrough clonal expansion of infected CD4+T-lymphocytes.25
owever, their levels remain stable over timeprobably because
peciﬁc HTLV-1 cytotoxic response of CD8 T-lymphocytes
liminates part of these infected cells.26 This study is limited
y the small sample size analyzed and by the short period
f time evaluated. Moreover, it was not possible to evaluate
atients continuously at the intervals of 12 months, 12 to 24
onths, and more than 24 months. Further studies, involv-
ng large number of individuals with a serial HTLV PVL could
omplete these results.
In summary, the results obtained indicated that HTLV-
-PVL of HTLV-1 infected individuals remains stable for 24
onths, in both asymptomatic and HAM/TSP patients. The
uthors recommend the annual measurement of PVL in
symptomatic individuals, aswell as themonitoring of patient
isease progression.onﬂict of interest
ll authors declare to have no conﬂict of interest.to compare the medians of proviral load.
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